Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Banks On DNA Repair To Challenge IO Space

Executive Summary

With a better understanding of how DNA damage repair (DDR) pathways operate in cancer cells, UK biotech Artios Pharma, in partnership with Cancer Research UK, is looking to develop drug candidates that can selectively kill tumor cells. Speaking at the Biotech Showcase 2018, Artios CEO Niall Martin told Scrip how the company is advancing its lead programs towards the clinic and is seeking series B venture capital to demonstrate proof of concept for the lead programs.

 

Advertisement

Related Content

Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel